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Malaria remains a significant global health burden and a 
vaccine would make a substantial contribution to malaria 
control. Chimpanzee Adenovirus 63 Modified Vaccinia 
Ankara Multiple epitope thrombospondin adhesion protein 
(ME-TRAP) and vaccination has shown significant efficacy 
against malaria sporozoite challenge in malaria-naive Euro-
pean volunteers and against malaria infection in Kenyan 
adults. Infants are the target age group for malaria vaccina-
tion; however, no studies have yet assessed T-cell responses 
in children and infants. We enrolled 138 Gambian and 
Burkinabe children in four different age-groups: 2–6 years 
old in The Gambia; 5–17 months old in Burkina Faso; 5–12 
months old, and also 10 weeks old, in The Gambia; and 
evaluated the safety and immunogenicity of Chimpanzee 
Adenovirus 63 Modified Vaccinia Ankara ME-TRAP  het-
erologous prime-boost immunization. The vaccines were 
well tolerated in all age groups with no vaccine-related seri-
ous adverse events. T-cell responses to vaccination peaked 
7 days after boosting with  Modified Vaccinia Ankara, with 
T-cell responses highest in 10 week-old infants. Heterolo-
gous prime-boost immunization with Chimpanzee Adeno-
virus 63 and Modified Vaccinia Ankara ME-TRAP was well 
tolerated in infants and children, inducing strong T-cell 
responses. We identify an approach that induces potent 
T-cell responses in infants, which may be useful for prevent-
ing other infectious diseases requiring cellular immunity.
Received 8 December 2015; accepted 23 March 2016; advance online  
publication 28 June 2016. doi:10.1038/mt.2016.83
INTRODUCTION
Malaria remains a significant public health problem, especially 
among under 5 years old children in Africa. Although widespread 
malaria control interventions have led to a remarkable decline in 
malaria associated deaths; there has been an increasing concern 
about emerging threats of resistance to artemisinin-based antima-
larial drugs and insecticide-treated nets.1 This concern has rekin-
dled the need for additional strategies in reducing the burden of 
malaria. One study also suggested that malaria associated death 
could be twice more than that was previously reported; with most 
deaths occurring in African children.2 An effective malaria vac-
cine has therefore been agreed to be a valuable complementary 
tool to optimize existing malaria control strategies and contribute 
to elimination of malaria in Africa.3
Current malaria vaccine candidates are directed against the 
human and mosquito stages of the parasite life cycle, but so far, 
the leading candidate RTS,S/AS01 has demonstrated only par-
tial protection among young African children,4,5 with subopti-
mal durability. Most candidate vaccines in clinical development 
are based on the classical vaccination approach of a single vac-
cine administered in a homologous prime–boost schedule which 
induce primarily neutralizing antibodies but weak CD4+ and no 
CD8+ T-cells.6 This approach may account for the inadequate 
protection generated by the candidate vaccines, and justifies the 
need for other approaches to induce and sustain strong T-cell 
responses and help alleviate the huge mortality associated with 
malaria. Hence, the innovative approach of combining different 
vaccine modalities to complement and induce broad and sustain-
able immunity was developed.6
Heterologous prime-boost regimens with adenovirus prim-
ing and MVA boosting are currently being developed for a wide 
range of diseases including respiratory syncytial virus, malaria, 
tuberculosis, human immunodeficiency virus, pandemic influ-
enza, hepatitis C, Ebola virus disease, and cancer.7–13 We report 
here the first evaluation of this approach to inducing T-cell and 
antibody responses in young children and infants. This is also to 
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our knowledge, the first evaluation of a simian adenovirus in chil-
dren or infants. Using the Chimpanzee Adenovirus 63 (ChAd63) 
and Modified Vaccinia Ankara ME-TRAP (MVA ME-TRAP) vec-
tors, we undertook phase 1 dose-escalation and age de-escalation 
studies to assess safety and immunogenicity in malaria-exposed 
children and infants.
Safety of human recombinant adenovirus vaccines has been 
assessed previously in infants aged 6–9 months that were immu-
nized with AERAS-402, a novel TB vaccine expressing three anti-
gens from Mycobacterium tuberculosis14 and an MVA encoding 
the antigen85A, MVA85A, has been assessed as a single dose vec-
tored vaccine in African infants in phase 1 and 2a trials.15,16 Here 
we describe the safety of a recombinant chimpanzee adenovirus 
in a prime-boost regimen with MVA boosting in younger infants 
aged 10 weeks at first immunization that would be the preferred 
target age for a malaria vaccine.
Two clinical trials were performed in Sukuta in the western 
region of The Gambia where malaria transmission has declined 
substantially since 2003, although modest levels of transmission 
occur following seasonal rains.17 The third study was undertaken 
in the Cascades region of south western Burkina Faso, where 
transmission is again highly seasonal, but with a much higher 
incidence of malaria than in The Gambia, with an average of two 
confirmed episodes per child per year.18 Both sites represent set-
tings whereas an effective malaria vaccine might be deployed use-
fully and we describe here safety profiles and preliminary T-cell 
responses from four groups of children of decreasing ages from 6 
years to 10 weeks old.
RESULTS
Safety and reactogenicity
In group 1 involving Gambian children aged 2–6 years, all adverse 
events (AEs) reported after vaccination with either high or low dose 
of ChAd63 ME-TRAP and MVA ME-TRAP were mild in inten-
sity, with pain at the injection site (7/24, 29%), and documented 
fever (3/24, 12.5%) the most frequently observed symptoms (see 
Supplementary Tables S1–S6). The higher dose of ChAd63 pro-
duced more local solicited AEs than the lower dose. Among par-
ticipants in group 2, Gambian infants aged 5–12 months, all AEs 
reported after vaccination with either dose of ChAd63 ME-TRAP 
were mild and resolved within 1 day of onset, with fever the most 
commonly reported symptom (4/24, 17%, among vaccinees versus 
2/24, 8% in unvaccinated controls).
Among group 3 participants, Gambian infants aged 10 weeks 
at first vaccination; all AEs related to ChAd63 ME-TRAP were 
mild and resolved within 1 day of onset. There were no unsolicited 
AEs related to ChAd63, however a single serious adverse event 
(SAE) was recorded due to hospital admission for gastroenteri-
tis on day 1, postvaccination that was considered unlikely to be 
related to vaccination. After administration of MVA ME-TRAP, 
eight AEs possibly related to vaccination occurred with fever the 
most commonly reported symptom (6/12, 50% of vaccinated 
infants, compared with 1/12, 8% unvaccinated controls). All were 
mild in intensity and all hematological and biochemical tests were 
within normal ranges. No child in groups 1–3 developed clini-
cal malaria during the study. Among the 30 Burkinabe infants 
and children aged 5–17 months in group 4, the safety profile was 
broadly similar to that observed in Gambian vaccine recipients 
aged 5–12 months (see Supplementary Tables S1–S6).
Immunogenicity
Dose-finding in group 1 in The Gambia. Children aged 2–6 
years (group 1) received either high or low dose ChAd63 ME-
TRAP boosted with either high or low dose MVA (Figure 1) or 
vaccinated with rabies vaccine as a control. An increase in ME-
TRAP-specific IFNγ-secreting T-cells as measured by Enzyme-
Linked ImmunoSpot (ELISPOT) assay was apparent after vacci-
nation with ChAd63 ME-TRAP in all children in group 1, aged 
2–6 years old (Figure 2a,c), compared with Human Diploid Cell 
Rabies Vaccine (HDCRV)-vaccinated controls. For those vacci-
nated with the higher dose of 5 × 1010 viral particles (vp) intramus-
cularly (i.m.) of ChAd63 ME-TRAP, the increase in ELISPOT 
response was significant compared with the recipients of rabies 
vaccine (groups 1d and 1e: 298 spot-forming cells (SFC) per mil-
lion peripheral blood mononuclear cell (PBMC)  with interquar-
tile range (IQR) 53–1040, compared with 1c and 1f: 28 SFC, IQR 
28–39 SFC, P = 0.004, Kruskal–Wallis Test).
After a booster vaccination with MVA ME-TRAP, IFNγ 
ELISPOT responses among recipients of the lower dose of MVA 
(1 × 108 pfu i.m.) increased significantly from baseline (Group 1a 
preboost: 69 SFC, IQR 33–180, postboost: 882 SFC, IQR 110–
1838, P < 0.05, Kruskal–Wallis test). Boosting with the higher dose 
of MVA (2 × 108 plaque-forming units (pfu) i.m.)  significantly 
increased responses compared with rabies vaccination (P < 0.01, 
Kruskal–Wallis test for groups 1b and 1e compared with 1c and 1f, 
Figure 2b). There was no significant effect of priming or boosting 
dose on the magnitude of the ELISPOT response at day 63 (1a 
compared with 1b and 1d compared with 1e, two-tailed Mann–
Whitney test).
Age de-escalation in groups 2, 3 and 4 in The Gambia and 
Burkina Faso. As no effect of dose was apparent in the first 
group; all children in the subsequent groups received 1 × 108 pfu 
i.m. of MVA ME-TRAP. Age de-escalation and dose escalation 
continued for ChAd63 ME-TRAP as adenoviral vectors have un-
dergone less evaluation in young children than MVA. ELISPOT 
data for the 5–12 months old group was incomplete due to poor 
lymphocyte viability, although in group 2b that received the high-
er dose of ChAd63 ME-TRAP the immune response peaked after 
MVA vaccination at 720 SFC (IQR 288–982 SFC), Figure 3a. In 
infants immunized at 10 weeks of age, there was a significant ef-
fect of dose after priming at day 21 after vaccination (P = 0.002, 
two-tailed Mann–Whitney test, Figure 3b), but after boosting 
with MVA there was no significant difference in responses be-
tween vaccinated groups (P = 0.24). Responses in vaccinated chil-
dren remained significantly above those in unvaccinated controls 
5 weeks after boosting (P < 0.05, Kruskal–Wallis with Dunn’s post 
test). In children aged 5–17 months vaccinated in Burkina Faso, 
responses increased slightly after boosting at day 21 and peaked 7 
days after boosting with MVA at 336 SFC (IQR 206–576, P < 0.001 
compared with prevaccination, Kruskal–Wallis test with Dunn’s 
post test, Figure 3c). Responses were still significantly higher than 
prevaccination, 6 months after the MVA immunization (72 SFC, 
IQR 35–128, P < 0.05, Kruskal–Wallis test with Dunn’s post-test).
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Figure 1 Participant flow chart for malaria vectored vaccine trials in Gambian and Burkinabe children and infants. (a) CONSORT flow chart for 
groups 1, 2, and 3 in The Gambia. (b) CONSORT flow chart for group 4 in Burkina Faso. 
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DISCUSSION
We report on the first use of a chimpanzee adenovirus vectored 
vaccine and of chimpanzee adenovirus prime—MVA boost regi-
mens in children and infants, and identify a surprising ability of 
these vectors to induce higher levels of T-cells compared with 
responses in adults.
Prime-boost vaccination with ChAd63 and MVA ME-TRAP 
has demonstrated an acceptable safety profile in four cohorts of 
children of decreasing ages in The Gambia and Burkina Faso. 
Vaccination was particularly well tolerated in the group of infants 
aged 10 weeks at the time of vaccination with ChAd63, where all 
vaccine-related AEs were mild and resolved within 1 day. In addi-
tion, this regimen elicited substantial cellular immunity in the 
younger age groups, with levels of TRAP-specific T-cells highest 
in 10-week-old babies.
Previous studies with the same antigen encoded in fowlpox and 
MVA vectors failed to elicit protection against malaria in Kenyan 
children aged 1–6 years due to reduced immunogenicity relative to 
malaria-naive adults, presumably due to malaria- associated immu-
nosuppression.19,20 The substitution in this regimen of the heterolo-
gous adenovirus for the fowlpox priming vector has increased the 
T-cell immunogenicity of this antigen 10-fold in the comparable 
Figure 2 Immune responses following ChAd63/MVA ME-TRAP vaccinations in Gambian children. (a) Individual responses by dose of ChAd63 
ME-TRAP 14 days after vaccination. Increases in response were significant in volunteers receiving 5 × 1010 vp i.m. compared with rabies vaccine 
(Groups 1d and 1e compared with 1c and 1f, P = 0.004, Kruskal–Wallis). Lines represent group median. (b) Individual responses 7 days after boost-
ing with MVA ME-TRAP (day 63), responses among recipients of the higher dose of MVA (2 × 108 pfu i.m.) increased significantly compared with 
rabies vaccination. Boosting with the lower dose of MVA (1 × 108 pfu i.m.) also increased responses significantly in group 1a. There was no significant 
effect of priming or boosting dose on the magnitude of the ELISPOT response at day 63 (1a compared with 1b or 1d compared with 1e, two-tailed 
Mann–Whitney test). (c) Time course of median ELISPOT responses in 2–6 years old children receiving either ChAd63-MVA ME-TRAP or HDCRV. 
Abbreviations: ChAd63, chimpanzee adenovirus serotype63; ME-TRAP, multiple epitope–thrombospondin-related adhesion protein; MVA, modified 
vaccinia virus Ankara; pfu, plaque-forming units; vp, viral particles; i.m., intramuscularly; HDCRV, human diploid cell rabies vaccine. All comparisons 
between time points use Kruskal–Wallis with Dunn’s multiple comparison test: *P < 0.05; **P < 0.01, ***P < 0.001.
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age groups, based on ex vivo ELISPOT responses. This demon-
strates the potency of the ChAd63 vector in combination with MVA 
encoding the same antigenic insert. Comparison of this regimen in 
Gambian and Kenyan adults was fourfold higher than in the fowl-
pox-MVA regimen, suggesting the potency of the ChAd63 vector 
may be higher in children than adults. A possible explanation for 
this is that the malaria-associated immunosuppression has less 
effect on responses to adenoviral vectors than poxviral vectors, per-
haps as a result of different receptor usage or stimulation of alterna-
tive pathways of innate immunity. T-cell responses remained above 
prevaccination thresholds for at least 6 months after boosting dem-
onstrating useful durability.
We report here a detailed analysis of the safety of ChAd63 and 
MVA ME-TRAP in four groups of African children that would 
benefit from an effective malaria vaccine. These vaccines show 
remarkable safety with very acceptable reactogenicity profiles for 
both vaccines at two dose levels, highlighting the potential util-
ity of these viral vectors for childhood immunization against 
other infections. We have described in detail the potent cellular 
immunogenicity of these vaccines in children aged 5–17 months 
in Burkina Faso and 5–12 months or 10 weeks old in The Gambia. 
This regimen is known to elicit CD8+ T-cell-mediated efficacy 
against CHMI in malaria-naive adults9 and therefore high frequen-
cies of similar T-cell populations in children that are the target for a 
malaria vaccine is a promising observation for future efficacy.
These data support further evaluation of this regimen in 
phase 2 studies, particularly in younger age groups of children to 
assess efficacy against malaria in regions of malaria transmission. 
Further trials are underway to assess efficacy in semi-immune 
adults and 5–17 months old infants and children, and to deter-
mine schedules for optimal deployment within the World Health 
Organization expanded program of immunization.
MATERIALS AND METHODS
Objectives. The primary objective was to evaluate the safety and reactoge-
nicity of the ChAd63 ME-TRAP and MVA ME-TRAP vaccines in malaria-
experienced Gambian and Burkinabe children. Secondary objectives were 
to evaluate the cellular and humoral immunogenicity of the vaccines in 
semiimmune Gambian and Burkinabe children in two settings of varying 
seasonal malaria transmission, while the tertiary objective was to com-
pare the immunogenicity of the low and high doses of MVA ME-TRAP 
(Gambian children only).
Study settings. The first clinical trial (group 1) took place from December 
2010 to December 2011 at the Sukuta field site of the Medical Research 
Council, The Gambia. Sukuta is a peri-urban village located about 30 km 
south of the capital Banjul. The Sukuta field site previously served as the base 
for the phase 1 trials of ChAd63 MVA ME-TRAP vaccine in adults (18 years). 
In this region, malaria transmission is highly seasonal, occurring almost 
exclusively during the rainy season (July to December) with greatest inci-
dence in September to November. Anopheles gambiae is the principal malaria 
vector. Previous studies have documented a decline in incidence of malaria in 
The Gambia17,21; however, an upsurge in malaria cases has been reported in 
different parts of the country.22 The second clinical trial (groups 2 and 3) took 
place in the same setting between September 2011 and March 2013.
The third clinical trial (group 4) took place from December 2012 
to September 2013 in Banfora Health District in the Cascades region of 
South Western Burkina Faso, about 400 km south-west from the capital 
Ouagadougou. Malaria transmission is stable during the year, with 
increased levels during the rainy season from May to November, peaking 
from May to September.18 A. gambiae is the principal malaria vector.
Participants. After local community meetings held by the trial teams in 
both sites, parents of potential participants were invited to the trial site 
for eligibility screening tests. Before enrolment, mothers gave a detailed 
medical history for the child. The child then underwent physical examina-
tion and laboratory evaluation of blood samples to determine suitability 
for enrolment. The children were eligible for enrolment if they were within 
the correct age group for the relevant study, in good health, a parent or 
guardian provided informed consent for participation in the study and 
residence in the study area was anticipated during the vaccination and fol-
low-up period. Exclusion criteria included any evidence of chronic illness 
or of hematological, renal or hepatic pathology: hemoglobin level <8 g/dl 
for children under 2 years or 9 g/dl for older children; severe malnutrition; 
positive malaria antigen test (Gambian trials only); positive HIV serology 
test for children above 2 years or positive maternal HIV test for younger 
children; clinically significant serum biochemistry results; prior receipt of 
an investigational malaria vaccine; recent or planned use of any investiga-
tional drug, vaccine, immunoglobulin or any blood product; use of immu-
nosuppressant drugs; confirmed or suspected immunodeficiency; history 
of surgical splenectomy; concurrent participation in another clinical trial.
Study design. We conducted three phase 1b studies. The first study (group 1, 
aged 2–6 years) in The Gambia was the pediatric arm of a phase 1b single-
blind, randomized controlled, dose-escalation study in adults that has 
been reported previously.23,24 The second study, also in The Gambia, was 
a subsequent single-blind randomized controled, dose-escalation study in 
children aged 5–12 months (group 2) and 10 weeks (group 3) at vaccina-
tion with ChAd63 ME-TRAP. The third study was a phase 1 open-label 
safety lead-in group of a larger phase 2b study in Burkina Faso in children 
aged 5–17 months at first vaccination (group 4). Protocols and CONSORT 
checklists are provided in Supplementary Information Protocol S1 (group 
1, The Gambia), Protocol S2 (groups 2 and 3, The Gambia), Protocol S3 
(group 4, Burkina Faso), and Checklists S1–S3. All vaccinations were intra-
muscular with group 1 receiving doses in the deltoid region of the arm, 
while all other groups were vaccinated in the anterolateral thigh. A control 
group was added to group 1 because of the anticipated high frequency of 
concurrent diseases in the study age group of 2–6 years and also to aid 
objective assessment of the relationship of AEs to vaccination.
Recruitment. Two hundred children were screened for eligibility across the 
three trials and 138 eligible children were enrolled, vaccinated, and fol-
lowed up (Figure 1). Two children from group 1 and two children from 
group 4 withdrew before follow up was completed. The parents of one 
study child in group 1, relocated outside the study area while the mother of 
another child withdrew consent before MVA boost vaccination. Similarly 
in group 4, mothers of two children withdrew consent before MVA boost 
vaccination. Trial groups are shown in Table 1. Baseline demographic data 
for each group are shown in Table 2.
Sample size. These phase 1b trials were not powered to detect differences 
between groups. The sample size was based on general acceptance of this 
size for initial assessment of safety, tolerability and immunogenicity of 
the investigational vaccines in a malaria endemic area and this size bal-
ances the need to avoid exposing a large group of study participants to an 
unknown risk with the need for useful safety and immunogenicity data 
from an adequate sample size.
Interventions. The Clinical Biomanufacturing Facility (CBF), University 
of Oxford, UK and IDT, Germany manufactured ChAd63 ME-TRAP and 
MVA ME-TRAP under Good Manufacturing Practice conditions, respec-
tively as previously described.9
Human Diploid Cell Rabies Vaccine (HDCRV, Sanofi Pasteur MSD, 
Mallards Reach, Berkshire, UK) was chosen as the comparator vaccine 
because rabies is endemic in The Gambia and antirabies vaccines were 
not readily accessible for preexposure prophylaxis; hence the investigators 
decided that giving HDCRV might benefit the study children. In groups 2 
and 3, notreatment controls were included, and there was also no control 
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group in group 4  as the subsequent larger phase 2 study had a rabies 
vaccine control arm.
Randomization in groups 1, 2 and 3, and blinding. An independent 
statistician at the Centre for Statistics in Medicine, Oxford performed a 
stratified randomization of participants (stratified by age into two catego-
ries and split by the median values of ages of children recruited). The list of 
eligible children after screening was sent to the statistician who carried out 
the randomization. The statistician had no knowledge of the participants, 
except the age, as this was required for the stratification. The children were 
randomly allocated to six groups in dose-escalated fashion. This was done 
to determine the tolerable doses as this was the first time ChAd63 and 
MVA.ME-TRAP vaccines were being administered to Gambian children. 
The investigators and the vaccinators were unblinded to the group allo-
cations. However, the study children’s parents/carers and field workers 
who conducted postvaccination assessment of reactogenicity and solicited 
symptoms were blinded to the group allocations.
For group 1, 36 eligible children were randomized to receive either 
group 1a: low dose ChAd63 ME-TRAP (1 × 1010 vp) followed by low dose 
MVA ME-TRAP (1 × 108 pfu); group 1b: low dose ChAd63 ME-TRAP 
(1 × 1010 vp) followed by high dose MVA ME-TRAP (2 × 108 pfu); group 
1c: Control HDCRV 1 ml followed by HDCRV 1 ml. Group 1d: high dose 
ChAd63 ME-TRAP (5 × 1010 vp) followed by low dose MVA ME-TRAP 
(1 × 108 pfu); group 1e: high dose ChAd63 ME-TRAP (5 × 1010vp) followed 
by high dose MVA ME-TRAP (2 × 108 pfu); group 1f: Control HDCRV 
1 ml followed by HDCRV 1 ml i.m. All vaccinations were separated by an 
eight-week interval.
For groups 2 and 3, 36 eligible children in each group were 
randomized to receive either group a: low dose ChAd63 ME-TRAP 
(1 × 1010vp) followed by low dose MVA ME-TRAP (1 × 108 pfu); group b: 
low dose ChAd63 ME-TRAP (1 × 1010 vp) followed by high dose MVA 
ME-TRAP (2 × 108 pfu); group c: no vaccine. For group 4, all 30 children 
received high dose ChAd63 ME-TRAP (5 × 1010 vp) followed by low dose 
MVA ME-TRAP (1 × 108 pfu).
Administration of ChAd63 ME-TRAP and MVA ME-TRAP 
occurred in three escalated stages. Each group was age stratified to ensure 
that any imbalance in safety and reactogenicity rates was not due to a 
disproportion of young children in any one cohort. Vaccinations of study 
children with ChAd63 ME-TRAP were staggered from each other by 2 
weeks and by 1 week in MVA-ME-TRAP vaccinations. A safety report was 
produced prior to each dose escalation and safety assessment approval by 
Local Safety Monitor (LSM) and Data Safety Monitoring Board (DSMB) 
was achieved before proceeding to the next stage. The LSM and DSMB 
also reviewed all AEs occurring in the 14 days immediately following 
any vaccination that preceded a dose escalation. Written approval from 
the DSMB and concurrence by the LSM were required prior to any 
subsequent dose escalation.
Outcomes. The primary endpoint was safety measured as (i) occurrence of 
solicited symptoms during a 3-day follow-up period after each immuniza-
tion; (ii) occurrence of unsolicited symptoms during a 28-day follow-up 
after each vaccination; (iii) occurrence of abnormal laboratory results dur-
ing study period; and (iv) occurrence of SAEs during the study period. The 
secondary outcomes were T-cell responses as determined by ELISPOT and 
flow cytometry with intracellular cytokine staining and anti-TRAP anti-
body titers. Time points for assessment of immunogenicity varied by trial 
according to logistical, ethical, and clinical considerations. For group 1, 
samples were collected on study days 0, 14, 56, 63, 90, and 300; for groups 
2 and 3, samples were collected on days 0, 21, 56, 63, and 105; for group 4, 
samples were collected on days 0, 21, 56, 63, and 243.
Assessment of primary endpoints (safety and reactogenicity). Adverse 
events were graded by intensity and judged for relatedness to study vac-
cines. Mild AEs were easily tolerated, causing minimal discomfort. 
Moderate AEs were sufficiently discomforting to interfere with normal 
activities. Severe adverse events prevented normal daily activities. Swelling, 
redness, and fever had specific definitions not based on interference with 
daily activities. Injection site swelling and redness were graded based on 
their widest dimension: mild, 0–20 mm; moderate, 20–50 mm; and severe 
>50 mm. Fever was classified as severe if the axillary temperature was 
≥40°C. For laboratory tests, toxicity grading was adapted to normal refer-
ence ranges determined for the local pediatric population.
Following each vaccination, all study children were directly observed 
in the clinic for 1 hour; followed up for occurrence of solicited symptoms 
for three consecutive days; unsolicited symptoms for 30 days, and 
laboratory abnormalities and SAEs for the entire study period. Trained 
field workers visited the children at home daily for the 3 days after each 
vaccination to administer a reactogenicity questionnaire to the parents/
Table 1 Study outline
Group Age Site N
First vaccine 
dose ChAd63 
ME-TRAP, vp
Second vaccine 
dose MVA  
ME-TRAP, pfu
1a 2–6 years The 
Gambia
6 1 × 1010 1 × 108
1b 6 1 × 1010 2 × 108
1c 6 HDCRV (1 ml) HDCRV (1 ml)
1d 6 5 × 1010 1 × 108
1e 6 5 × 1010 2 × 108
1f 6 HDCRV (1 ml) HDCRV (1 ml)
2a 5–12 months The 
Gambia
12 1 × 1010 1 × 108
2b 12 5 × 1010 1 × 108
2c 12 No vaccine No vaccine
3a 10 weeks The 
Gambia
12 1 × 1010 1 × 108
3b 12 5 × 1010 1 × 108
3c 12 No vaccine No vaccine
4 5–17 months Burkina 
Faso
30 5 × 1010 1 × 108
HDCRV, human diploid cell rabies vaccine; ME-TRAP, multiple epitope–throm-
bospondin-related adhesion protein; MVA, modified vaccinia virus Ankara; pfu, 
plaque-forming units; vp, viral particles. Notes: Groups 1c and 1f are identi-
cal; however, they were recruited at the same time as groups 1a/b and 1e/f, 
 respectively, to take account of seasonal variation in nonvaccine related adverse 
events.
Table 2 Baseline demographics of enrolled trial participants
Site The Gambia Burkina Faso
Age group 2–6 years 5–12 months 10 weeks 5–17 months
Study group 1a 1b 1c 1d 1e 1f 2a 2b 2c 3a 3b 3c 4
N 6 6 6 6 6 6 12 12 12 12 12 12 30
Median age, interquartile range (IQR) 44 months (36–51) 8 months (5.5–8.5) 10 weeks 44 weeks (36–61)
Gender ratio (M/F) 0.64 (23/13) 0.61 (22/14) 0.69 (25/11) 0.5 (15/15)
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guardians that included history of fever, vomiting, diarrhea, reduced oral 
intake, and reduced activities. The field worker also examined the child 
for expected local AEs (swelling, tenderness, limitation of arm movement, 
redness, and desquamation at the site of injection) and fever. Pain at the 
injection site was graded on a scale of 0–3 (where 0 = no pain, 1 = painful 
to touch, 2 = pain when arm is touched, and 3 = severe pain at rest).
The study participants were subsequently evaluated at the clinic 
on study days 14, 63, 90, and 300. Clinical evaluations consisted of 
measurement of vital signs and assessment for local injection site, 
general solicited symptoms and signs. Local solicited symptoms and 
signs included pain, swelling, and redness at injection site, while systemic 
solicited symptoms and signs included fever (axillary temperature 
>38°C), reduced oral intake, reduced activity, and vomiting. Any other 
symptoms or signs were considered to be unsolicited. Solicited symptoms 
were considered to be related to the study vaccines. Unsolicited symptoms 
and signs were recorded during the 30 days after each vaccination while 
SAEs were monitored throughout the study period. Blood samples were 
collected at screening, on vaccination days and study days 14, 63, 90, and 
300 to determine complete blood count, alanine aminotransferase, and 
serum creatinine.
Blood processing. Blood samples were stored at room temperature prior to 
processing, which was completed within 6 hours of venepuncture. PBMC 
were separated by density gradient centrifugation from heparinized whole 
blood and resuspended in Roswell Park Memorial Institute medium con-
taining 10% heat-inactivated, batch-tested, and sterile-filtered fetal bovine 
serum (Labtech International), 1% L-glutamine, and 1% penicillin/strep-
tomycin. Cell counts were performed using Trypan blue staining and a 
microscope according to an established standard operating procedure in 
the lab. Blood processing was harmonized between the labs in The Gambia 
and Burkina Faso. ELISPOT assays performed in the adult trial were per-
formed in the same laboratory and were harmonized with procedures in 
these studies.
Ex vivo ELISPOT assays. Ex vivo (18 hours stimulation) ELISPOT 
assays were performed using Multiscreen IP ELISPOT plates (Millipore, 
Watford, UK), human IFNγ SA-ALP antibody kits (Mabtech, Nacka, 
Sweden) and BCIP NBT-plus chromogenic substrate (Moss, Pasadena, 
MD). Cells were cultured in Roswell Park Memorial Institute medium 
(Sigma, St.Louis, MO) containing 10% heat-inactivated, sterile-fil-
tered fetal calf serum, previously screened for low reactivity (Labtech 
International, East Sussex, UK), supplemented with 1% L-glutamine and 
1% penicillin/streptomycin. Antigens were tested in duplicate with either 
200,000 or 250,000 PBMC added to each well of the ELISPOT plate. 
TRAP peptides were 20 amino acids in length, overlapping by 10 amino 
acids (NeoBioLab, London, UK), assayed in six pools of 7–10 peptides 
at 10 μg/ml. Responses were averaged across duplicates, responses in 
unstimulated (negative control) wells were subtracted and then responses 
in individual pools were summed for each strain of the TRAP antigen 
Staphylococcal enterotoxin B (0.02 μg/ml) and phytohemmagglutinin-L 
(10 μg/ml) were used as a positive control. Plates were counted using an 
AID automated ELISPOT counter (AID Diagnostika GmbH, Strassberg, 
Germany algorithm C), using identical settings for all plates, and counts 
were adjusted only to remove artifacts. Responses to the negative control 
were always <154 SFC per million PBMC and the median across all tri-
als was 12 SFC per million PBMC. Pools were considered positive if the 
response was >12 SFC per million PBMC and two times higher than the 
negative control for that assay. The lower limit of detection for the assay 
was 28 SFC for ME-TRAP.
Statistical methods. Data entry was double-entered on OpenClinica® soft-
ware and analyses performed using STATA Release statistical software ver-
sion 11.1 (StataCorp LP, College Station, TX). For categorical variables, 
data were summarized using numbers and percentages. The incidence 
of solicited and unsolicited adverse events was compared between the 
comparator and test vaccine groups using Fisher’s exact test. For continu-
ous variables, the median, and interquartile range or geometric means 
with 95% confidence intervals (CI) were used to summarize the data. 
Participants were analyzed according to the treatments they received.
Group data are geometric means unless otherwise stated with 95% CI. 
The matched pair analysis excludes volunteers with missing data at any 
time point. A Kruskal–Wallis test was used to compare increases in T-cell 
frequencies in time courses with Dunn’s multiple comparisons post-
test used to compare response pre and postvaccination. For statistical 
analyses, an alpha-level of 0.05 was considered significant and all P-values 
are two-tailed. All analyses were performed in GraphPad Prism, Mac 
version 6. (GraphPad Software, La Jolla CA).
Ethics and regulatory approval. An independent DSMB was appointed 
before the trials began to provide oversight and review the safety data 
reports as the trials progressed. Experienced local pediatricians served 
as LSM and, along with the DSMB, reviewed all safety data between dose 
escalations. In addition, trials were conducted according to ICH Good 
Clinical Practice guidelines and were monitored by an external organi-
zation (Appledown Clinical Research., Gt Missenden, Bucks, UK). The 
Gambian Government/Medical Research Council Joint Ethics Committee, 
The Gambia Medicines Board, the Burkina Faso Ministry of Health and 
Institutional Bioethics Committee, the UK Medicines and Healthcare 
products Regulatory Authority and Oxford Tropical Research Ethics 
Committee (OXTREC Numbers: 64-09, 26-11, 41-12) granted approval of 
the study protocol. All three trials were registered with http://www.clini-
caltrials.gov/.
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